期刊文献+

老年性骨质疏松症相关问题研究进展 被引量:84

Research progress of relevant problems for senile osteoporosis
下载PDF
导出
摘要 老年性骨质疏松症是指65岁以上女性和70岁以上男性人群发生的骨质疏松,是一种代谢性骨病,与绝经后妇女骨质疏松症的发病机制不同,发生主要与年龄有关,发病机制复杂,治疗上目前也无确切有效的药物。近年来,老年性骨质疏松发病率逐渐上升,严重影响老年人的生活质量。本文复习相关文献,就老年性骨质疏松症的病因、发病机制及治疗手段等相关问题进行综述,以期引起人们对老年性骨质疏松症的关注。 Senile osteoporosis refered to the patient in women more than 65 years old and 70 years old in older men,which was a metabolic bone disease,With the pathogenesis of postmenopausal osteoporosis,mainly related to age.The pathogenesis of complex,treatment was currently no effective drug for sure.In recent years,the incidence of senile osteoporosis gradually rise,which seriously affected the quality of life of the elderly.This paper reviewthe related literature,senile osteoporosis etiology,pathogenesis and treatment of related problems were reviewed,in order to arouse people to the attention of senile osteoporosis.
作者 丁超 孙强
出处 《中国骨质疏松杂志》 CAS CSCD 北大核心 2016年第3期372-375,共4页 Chinese Journal of Osteoporosis
基金 中国博士后科学基金面上项目(2012M511781)
关键词 老年性骨质疏松 发病机制 治疗方法 Senile osteoporosis Pathogenesis Treatment
  • 相关文献

参考文献1

二级参考文献46

  • 1Ebeling PR. Approach to the patient withtransplantation-related bone loss. J Clin Endocrinol Metab2009; 94: 1483-1490.
  • 2Lopez Oliva MO, Del Castillo Caba D,Sanchez Plumed J.Changes in bone and mineral metabolism in kidney transplantpatients with chronic kidney disease. Nefrologia 2009; 29:31-37.
  • 3Frediani B. Effects of two administration schemes ofintramuscular clodronic acid on bone mineral density: arandomized, open-label, parallel-group study. Clin DrugInvestig 2011; 31: 43-50.
  • 4Kimmel DB. Mechanism of action, pharmacokinetic andpharmacodynamic profile, and clinical applications ofnitrogen-containing bisphosphonates. J Dent Res 2007; 86:1022-1033.
  • 5Bone HQ Hosking D,Devogelaer JP, Tucci JR,Emkey RD,Tonino RP,et al. Ten years experience with alendronate forosteoporosis in postmenopausal women. N Engl J Med 2004;350:1189-1199.
  • 6Bone HQ Hosking D,Devogelaer JP, Tucci JR,Emkey RD,Tonino RP,et al. Ten years experience with alendronate forosteoporosis in postmenopausal women. N Engl J Med 2004;350:1189-1199.
  • 7Compston JE. Bisphosphonates and atypical femoralfractures: a time for reflection. Maturitas 2009; 65: 3-4.
  • 8Ott SM. Long-term safety of bisphosphonates. J ClinEndocrinol Metab 2005; 90: 1897-1899.
  • 9Recker RR,Lewiecki EM, Miller PD, Reiffel J. Safety ofbisphosphonates in the treatment of osteoporosis. Am J Med2009; 122 (2 Suppl): S22-S32.
  • 10Solomon DH, Rekedal L, Cadarette SM. Osteoporosistreatments and adverse events. Curr Opin Rheumatol 2009;21:363-368.

共引文献3

同被引文献774

引证文献84

二级引证文献1028

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部